Genomic copy number alterations as biomarkers for triple negative pregnancy-associated breast cancer.
Biomarkers
Breast cancer
Copy number alteration
MLPA
Pregnancy
Journal
Cellular oncology (Dordrecht)
ISSN: 2211-3436
Titre abrégé: Cell Oncol (Dordr)
Pays: Netherlands
ID NLM: 101552938
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
accepted:
02
06
2022
pubmed:
7
7
2022
medline:
1
9
2022
entrez:
6
7
2022
Statut:
ppublish
Résumé
PABC, commonly defined as breast cancer diagnosed during or ≤ 1 year after pregnancy, accounts for 7% of all breast cancers in women ≤ 45 years. Compared to age-matched non-PABC patients, PABC is characterized by a particularly aggressive histopathologic profile with poorly differentiated and estrogen- and progesterone receptor negative tumors and associated high mortality rates. This study assessed the genomic background of triple-negative PABC tumors by detection of copy number alterations (CNAs). MLPA was used to compare CNAs in breast cancer-associated chromosomal loci between triple-negative PABC- and subtype-matched non-PABC patients. Both CNA patterns were evaluated by cluster analysis; associations between individual gene CNAs, pathological characteristics and survival were explored. Triple-negative PABC tumors exhibited unique CNAs compared to non-PABC tumors, including enrichment for TOP2A copy number loss, an independent predictor of worse overall survival (HR 8.96, p = 0.020). Cluster analysis based on CNA profiles identified a triple-negative PABC-subgroup with a particularly poor prognosis, characterized by chromosome 8p copy number loss. Individual gene CNAs analysis revealed that FGFR1 copy number loss on chromosome 8p11.23 was an independent predictor of poor outcome in multivariate analysis (HR 3.59, p = 0.053) and predicted the development of distant metastases (p = 0.048). This study provides novel insights into the biology of triple-negative PABC tumors suggesting that CNAs, particularly 8p loss and TOP2A loss, are involved in the development of breast cancer during pregnancy. FGFR1 loss and TOP2A loss seem to be promising new biomarkers that independently identify subgroups of PABC patients with poor prognosis. These genomic biomarkers may provide clues for personalized therapy.
Sections du résumé
BACKGROUND
BACKGROUND
PABC, commonly defined as breast cancer diagnosed during or ≤ 1 year after pregnancy, accounts for 7% of all breast cancers in women ≤ 45 years. Compared to age-matched non-PABC patients, PABC is characterized by a particularly aggressive histopathologic profile with poorly differentiated and estrogen- and progesterone receptor negative tumors and associated high mortality rates. This study assessed the genomic background of triple-negative PABC tumors by detection of copy number alterations (CNAs).
METHODS
METHODS
MLPA was used to compare CNAs in breast cancer-associated chromosomal loci between triple-negative PABC- and subtype-matched non-PABC patients. Both CNA patterns were evaluated by cluster analysis; associations between individual gene CNAs, pathological characteristics and survival were explored.
RESULTS
RESULTS
Triple-negative PABC tumors exhibited unique CNAs compared to non-PABC tumors, including enrichment for TOP2A copy number loss, an independent predictor of worse overall survival (HR 8.96, p = 0.020). Cluster analysis based on CNA profiles identified a triple-negative PABC-subgroup with a particularly poor prognosis, characterized by chromosome 8p copy number loss. Individual gene CNAs analysis revealed that FGFR1 copy number loss on chromosome 8p11.23 was an independent predictor of poor outcome in multivariate analysis (HR 3.59, p = 0.053) and predicted the development of distant metastases (p = 0.048).
CONCLUSION
CONCLUSIONS
This study provides novel insights into the biology of triple-negative PABC tumors suggesting that CNAs, particularly 8p loss and TOP2A loss, are involved in the development of breast cancer during pregnancy. FGFR1 loss and TOP2A loss seem to be promising new biomarkers that independently identify subgroups of PABC patients with poor prognosis. These genomic biomarkers may provide clues for personalized therapy.
Identifiants
pubmed: 35792986
doi: 10.1007/s13402-022-00685-6
pii: 10.1007/s13402-022-00685-6
pmc: PMC9424154
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
591-600Informations de copyright
© 2022. The Author(s).
Références
Int J Cancer. 1997 Sep 4;72(5):720-7
pubmed: 9311584
J Clin Oncol. 2011 Mar 1;29(7):859-67
pubmed: 21189395
Breast Cancer Res Treat. 2017 Jun;163(3):417-421
pubmed: 28365832
Front Oncol. 2019 Aug 06;9:556
pubmed: 31448219
Oncotarget. 2018 Mar 30;9(24):17078-17092
pubmed: 29682206
J Thorac Dis. 2013 Jun;5 Suppl 1:S62-7
pubmed: 23819029
Cytojournal. 2012;9:4
pubmed: 22363393
Springerplus. 2015 Nov 19;4:710
pubmed: 26618099
Diagnostics (Basel). 2020 May 05;10(5):
pubmed: 32380689
Cancer Res. 2013 Mar 1;73(5):1454-60
pubmed: 23271725
J Natl Cancer Inst. 2009 May 6;101(9):644-50
pubmed: 19401546
Front Oncol. 2020 Sep 11;10:1773
pubmed: 33014874
BMJ. 2002 Sep 21;325(7365):648-51
pubmed: 12242180
Thorac Cancer. 2019 May;10(5):1060-1068
pubmed: 30920126
Genes Cancer. 2018 Jan;9(1-2):66-77
pubmed: 29725504
J Clin Oncol. 2005 Oct 20;23(30):7483-90
pubmed: 16234514
Nat Rev Cancer. 2004 Mar;4(3):177-83
pubmed: 14993899
J Clin Oncol. 2015 May 20;33(15):1680-7
pubmed: 25897160
Int J Cancer. 2018 Apr 1;142(7):1343-1354
pubmed: 29168177
Elife. 2018 Dec 11;7:
pubmed: 30526857
Cancer. 2019 Nov 1;125(21):3714-3728
pubmed: 31318440
Cancer. 2009 Mar 15;115(6):1174-84
pubmed: 19204903
World J Surg Oncol. 2021 Mar 23;19(1):86
pubmed: 33757543
Oncogene. 2004 Jul 22;23(33):5697-702
pubmed: 15184884
Obstet Gynecol. 2009 Sep;114(3):568-572
pubmed: 19701036
Cancer. 2012 Jul 1;118(13):3254-9
pubmed: 22086863
Cell Oncol. 2007;29(1):19-24
pubmed: 17429138
Obstet Gynecol. 2008 Jul;112(1):71-8
pubmed: 18591310
Am J Obstet Gynecol. 2003 Oct;189(4):1128-35
pubmed: 14586366
Cancer. 2003 Sep 1;98(5):1055-60
pubmed: 12942575
Mol Oncol. 2012 Aug;6(4):428-36
pubmed: 22626971
Breast Cancer Res Treat. 2013 May;139(1):183-92
pubmed: 23576078
Anticancer Res. 2000 Jul-Aug;20(4):2537-9
pubmed: 10953323
Genes Chromosomes Cancer. 2019 Jun;58(6):381-391
pubmed: 30597648
Breast. 2018 Aug;40:10-15
pubmed: 29665447
NPJ Breast Cancer. 2018 Aug 6;4:23
pubmed: 30109263
BMC Cancer. 2020 Aug 10;20(1):746
pubmed: 32778072
J Clin Oncol. 2013 Jul 10;31(20):2532-9
pubmed: 23610117
Nucleic Acids Res. 2015 Jul 1;43(W1):W566-70
pubmed: 25969447
BMC Cancer. 2019 Jan 21;19(1):96
pubmed: 30665374
Breast. 2019 Jun;45:15-21
pubmed: 30818144
Cell Oncol. 2010 Jan 1;32(4):311-2
pubmed: 20442492
Cell Cycle. 2015;14(12):1786-98
pubmed: 25789852
Cancer Cell. 2016 May 9;29(5):751-766
pubmed: 27165746
Breast. 2012 Aug;21(4):550-5
pubmed: 22698618
Mod Pathol. 2010 Jul;23(7):1029-39
pubmed: 20473280
Breast Cancer Res Treat. 2021 Apr;186(3):699-704
pubmed: 33635448
Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):11139-44
pubmed: 25024180
Cancer Res. 2009 May 1;69(9):3795-801
pubmed: 19336569
Front Oncol. 2020 Oct 30;10:583314
pubmed: 33194720
Clin Cancer Res. 2002 May;8(5):1107-16
pubmed: 12006526
JAMA Oncol. 2015 Sep;1(6):814-9
pubmed: 26355862
Breast Cancer Res Treat. 2018 Nov;172(1):113-121
pubmed: 30088177
Semin Cancer Biol. 2005 Aug;15(4):319-26
pubmed: 16043362
Cancer Biol Ther. 2015;16(7):1080-7
pubmed: 25961141
Pathol Oncol Res. 2014 Jul;20(3):581-90
pubmed: 24357159